



## Rhythm Pharmaceuticals to Provide Update on Phase 2 Basket Study and Genetic Sequencing Efforts

January 19, 2021

BOSTON, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it plans to host a virtual event on Tuesday, January 26, 2021 from 8 to 10 a.m. ET to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.

At the event, Rhythm management plans to report data for setmelanotide in individuals living with heterozygous (HET) obesity due to genetic variants in one of two alleles of the *POMC*, *PCSK1* or *LEPR* gene, as well as *SRC1* and *SH2B1* deficiency obesities, and plans to provide an update on data from the Company's sequencing efforts, which now comprises samples from approximately 37,500 individuals with severe obesity.

A live webcast of the event will be available under "Events & Presentations" in the Investors & Media section of the Company's website at <http://www.rhythmtx.com>. A replay of the webcast will be available on the Rhythm website for 30 days following the event.

### About Rhythm Pharmaceuticals

Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity. The company's precision medicine, IMCIVREE™ (setmelanotide), has been approved by the FDA for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to *POMC*, *PCSK1* or *LEPR* deficiency confirmed by genetic testing. IMCIVREE is the first-ever FDA approved therapy for these rare genetic diseases of obesity. Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity. The Company is leveraging the Rhythm Engine and the largest known obesity DNA database - now with more than 30,000 sequencing samples - to improve the understanding, diagnosis and care of people living with severe obesity due to certain genetic deficiencies. For healthcare professionals, visit [www.UNcommonObesity.com](http://www.UNcommonObesity.com) for more information. For patients and caregivers, visit [www.LEADforRareObesity.com](http://www.LEADforRareObesity.com) for more information. The company is based in Boston, MA.

### IMCIVREE™ (setmelanotide) Indication

IMCIVREE is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (*POMC*), proprotein convertase subtilisin/kexin type 1 (*PCSK1*), or leptin receptor (*LEPR*) deficiency. The condition must be confirmed by genetic testing demonstrating variants in *POMC*, *PCSK1*, or *LEPR* genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (*VUS*).

### Limitations of Use

IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective:

- Obesity due to suspected *POMC*, *PCSK1*, or *LEPR* deficiency with *POMC*, *PCSK1*, or *LEPR* variants classified as benign or likely benign; and
- Other types of obesity not related to *POMC*, *PCSK1* or *LEPR* deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.

### Important Safety Information

#### WARNINGS AND PRECAUTIONS

**Disturbance in Sexual Arousal:** Sexual adverse reactions may occur in patients treated with IMCIVREE. Spontaneous penile erections in males and sexual adverse reactions in females occurred in clinical studies with IMCIVREE. Instruct patients who have an erection lasting longer than 4 hours to seek emergency medical attention.

**Depression and Suicidal Ideation:** Some drugs that target the central nervous system, such as IMCIVREE, may cause depression or suicidal ideation. Monitor patients for new onset or worsening of depression. Consider discontinuing IMCIVREE if patients experience suicidal thoughts or behaviors.

**Skin Pigmentation and Darkening of Pre-Existing Nevi:** IMCIVREE may cause generalized increased skin pigmentation and

darkening of pre-existing nevi due to its pharmacologic effect. This effect is reversible upon discontinuation of the drug. Perform a full body skin examination prior to initiation and periodically during treatment with IMCIVREE to monitor pre-existing and new skin pigmentary lesions.

**Risk of Serious Adverse Reactions Due to Benzyl Alcohol Preservative in Neonates and Low Birth Weight Infants:**  
IMCIVREE is not approved for use in neonates or infants.

#### **ADVERSE REACTIONS**

- The most common adverse reactions (incidence  $\geq 23\%$ ) were injection site reactions, skin hyperpigmentation, nausea, headache, diarrhea, abdominal pain, back pain, fatigue, vomiting, depression, upper respiratory tract infection, and spontaneous penile erection.

#### **USE IN SPECIFIC POPULATIONS**

Discontinue IMCIVREE when pregnancy is recognized unless the benefits of therapy outweigh the potential risks to the fetus. Treatment with IMCIVREE is not recommended for use while breastfeeding.

To report SUSPECTED ADVERSE REACTIONS, contact Rhythm Pharmaceuticals at +1 (833) 789-6337 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

See [Full Prescribing Information](#) for IMCIVREE.

#### **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical progress of setmelanotide, the anticipated timing for release of clinical data, data to be presented in the upcoming presentation and our business strategy and plans. Statements using words such as "expect", "anticipate", "believe", "may", "will" and similar terms are also forward-looking statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, risks associated with data analysis and reporting, the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies, clinical trials and commercialization prospects, and the other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

#### **Corporate Contact:**

David Connolly  
Head of Investor Relations and Corporate Communications  
Rhythm Pharmaceuticals, Inc.  
857-264-4280  
[dconnolly@rhythmtx.com](mailto:dconnolly@rhythmtx.com)

#### **Investor Contact:**

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)

#### **Media Contact:**

Adam Daley  
Berry & Company Public Relations  
212-253-8881  
[adaley@berrypr.com](mailto:adaley@berrypr.com)



Source: Rhythm Pharmaceuticals, Inc.